The Role of Cytochrome P450 Holoenzyme Metabolism in the Origin of Neuropathologies. [PDF]
Štambuk S.
europepmc +1 more source
Old dog, new trick: Charybdotoxin as a novel ryanodine receptor blocker
Abstract figure legend The peptide toxin charybdotoxin (ChTx) from the scorpion Leiurus quinquestriatus was tested on single‐channel currents of the ryanodine receptor incorporated into planar lipid bilayers. The structure–function relationship of ChTx was investigated using toxin variants generated by isosteric substitutions of the basic amino acids ...
Zsuzsanna Édua Magyar +10 more
wiley +1 more source
The Effect of Artemisinin on the Pharmacokinetics of Cyclophosphamide and Its Metabolite in Mice and Its Potential Mechanisms. [PDF]
Wang H, Zhang W, Hu H, Wang S, Xie Y.
europepmc +1 more source
An Ultra-Fast UPLC-MS/MS Method for Quantifying Ivosidenib: Application to Assessment of Metabolic Stability in Human Liver Microsomes. [PDF]
Attwa MW +3 more
europepmc +1 more source
<i>In Vitro</i> characterization of narciclasine: solubility, metabolic stability, and P-glycoprotein substrate status. [PDF]
Akkireddy R +5 more
europepmc +1 more source
Investigating the Impact of Calcium Channel Blockers on the Pharmacokinetics of Lapatinib: Possible Role of Cytochrome P450 Enzymes and P-glycoprotein Efflux Transporters. [PDF]
Desai MP +4 more
europepmc +1 more source
Oxidation of Uroporphyrinogens During Heme Synthesis: Role of Iron, Susceptibility and Consequences. [PDF]
Smith AG.
europepmc +1 more source
Modular assembly and property profiling of an expansive, shape-defined library of pentacyclic saturated N-heterocycles. [PDF]
Boschi E +12 more
europepmc +1 more source
First-in-Human Dose Selection, Pharmacokinetics Prediction, and Clinical Validation of SYHA1805, a Novel FXR Agonist, Using Allometric Scaling and PBPK Modeling. [PDF]
Zhang L +6 more
europepmc +1 more source
IV-EVE: EVE for Injection-ADME, Pharmacokinetic and Toxicological Evaluation for Novel Deciparticle EVE Formulation. [PDF]
Chang WH +7 more
europepmc +1 more source

